ALIMTA (Pemetrexed) Alone or in Combination With Cisplatin for Patients With Malignant Mesothelioma.

NCT ID: NCT00040625

Last Updated: 2007-03-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

APPROVED_FOR_MARKETING

Study Classification

EXPANDED_ACCESS

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is to evaluate the effects (good and bad) of ALIMTA and Cisplatin or ALIMTA alone on you and your malignant pleural mesothelioma as well as make ALIMTA available to patients who qualify for treatment.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Mesothelioma

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Pemetrexed

Intervention Type DRUG

Cisplatin

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Have a proven diagnosis of malignant mesothelioma in patients not candidates for curative surgery
* Prior chemotherapy for your disease is allowed
* Measurable lesion is not required
* Have a adequate performance status
* Sign an informed consent form

Exclusion Criteria

* You are excluded from this trial if you have received any investigational agent within 4 week before enrolling in this study
* You are excluded from this trial if you have received radiation within the previous 2 weeks
* You are excluded from this trial if you are a candidates for curative surgery
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Eli Lilly and Company

INDUSTRY

Sponsor Role lead

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.

Basking Ridge, New Jersey, United States

Site Status

For additional information regarding investigative sites for this trial, contact the Clinical Trials support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician

Porto Alegre, Rio Grande do Sul, Brazil

Site Status

For additional information regarding investigative sites for this trial, contact the Clinical Trials support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician

São Paulo, , Brazil

Site Status

"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician."

Cairo, , Egypt

Site Status

For additional information regarding investigative sites for this trial, contact the Clinical Trials support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician

Cairo, , Egypt

Site Status

For additional information regarding investigative sites for this trial, contact the Clinical Trials support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician

Jeddah, , Saudi Arabia

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Brazil Egypt Saudi Arabia

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

H3E-US-JMFE

Identifier Type: -

Identifier Source: secondary_id

6093

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.